(Q41737284)

8 October 2017

1 reference

title

Impact of structural heart disease on the selection of class III antiarrhythmics for the prevention of atrial fibrillation and flutter (English)

1 reference

8 October 2017

1 reference

Reiffel JA

1

1 reference

PubMed ID

9539466

8 October 2017

language of work or name

English

0 references

publication date

1 April 1998

1 reference

8 October 2017

American Heart Journal

1 reference

8 October 2017

135

1 reference

8 October 2017

4

1 reference

8 October 2017

551-556

1 reference

"In the absence of structural heart disease...." What is it, and why does it matter in antiarrhythmic drug therapy?

8 October 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970266-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970266-2

Genesis of arrhythmias in the failing heart and therapeutic implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970266-2

Pharmacological therapy of arrhythmias complicating dilated cardiomyopathy--implications of the arrhythmogenic substrate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970266-2

Evolutionary paths in arrhythmia management: influences of substrate, studies, and seismology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970266-2

Mechanisms and risk factors for proarrhythmia with type Ia compared with Ic antiarrhythmic drug therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970266-2

Risk factors for the development of proarrhythmic events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970266-2

Clinical predictors of arrhythmia worsening by antiarrhythmic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970266-2

Proarrhythmic effects of antiarrhythmic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970266-2

Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970266-2

Sotalol. An updated review of its pharmacological properties and therapeutic use in cardiac arrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970266-2

Short- and long-term antiarrhythmic and hemodynamic effects of d,l-sotalol in patients with symptomatic ventricular arrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970266-2

Clinical safety profile of sotalol in patients with arrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970266-2

Sotalol-induced torsade de pointes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970266-2

Sotalol-induced torsade de pointes: management with magnesium infusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970266-2

Sotalol-induced torsades de pointes in a patient with pre-existent normal response to programmed ventricular stimulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970266-2

Clinical role of d-sotalol and d,l-sotalol in supraventricular arrhythmias, including pre-excitation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970266-2

Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970266-2

Oral sotalol reduces the incidence of atrial fibrillation after coronary artery bypass surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970266-2

Intravenous sotalol for the treatment of atrial fibrillation and flutter after cardiopulmonary bypass. Comparison with disopyramide and digoxin in a randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970266-2

Effectiveness of sotalol in preventing supraventricular tachyarrhythmias shortly after coronary artery bypass grafting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970266-2

Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970266-2

Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970266-2

Effects of amiodarone versus quinidine and verapamil in patients with chronic atrial fibrillation: results of a comparative study and a 2-year follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970266-2

Effectiveness of amiodarone and electrical cardioversion for chronic rheumatic atrial fibrillation after mitral valve surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970266-2

Amiodarone: clinical efficacy and toxicity in 96 patients with recurrent, drug-refractory arrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970266-2

Safety and efficacy of amiodarone. The low-dose perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970266-2

Low-dose amiodarone for atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970266-2

Amiodarone-induced polymorphous ventricular tachycardia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970266-2

Amiodarone and torsade de pointes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970266-2

Amiodarone in patients with previous drug-mediated torsade de pointes. Long-term safety and efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970266-2

Amiodarone for maintenance of sinus rhythm after conversion of atrial fibrillation in the setting of a dilated left atrium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970266-2

Amiodarone for refractory atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970266-2

Efficacy of amiodarone for refractory supraventricular tachyarrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970266-2

Use of amiodarone in the treatment of persistent and paroxysmal atrial fibrillation resistant to quinidine therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970266-2

Amiodarone in the management of refractory atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970266-2

Early after-depolarizations and torsade de pointes: implications for the control of cardiac arrhythmias by prolonging repolarization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970266-2

Controlled trial of sotalol for one year after myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970266-2

Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970266-2

Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970266-2

Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE Study). The CASCADE Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970266-2

Drugs with a class III antiarrhythmic action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970266-2

New class III antiarrhythmic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970266-2

Antiarrhythmic drugs and torsade de pointes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970266-2

The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970266-2

Electrophysiologic substrate of torsade de pointes: dispersion of repolarization or early afterdepolarizations?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970266-2

Recording of monophasic action potentials of the right ventricle in long QT syndromes complicated by severe ventricular arrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970266-2

Canine left ventricular hypertrophy predisposes to ventricular tachycardia induction by phase 2 early afterdepolarizations after administration of BAY K 8644

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970266-2

Slow conduction and reentry in the ventricular conducting system. II. Single and sustained circus movement in networks of canine and bovine Purkinje fibers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970266-2

10.1016/S0002-8703(98)70266-2

7 January 2021

Identifiers

DOI

1 reference

release_lqw6sjenara7pl6kcy5vkpffxq

8 October 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/lqw6sjenara7pl6kcy5vkpffxq

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

9539466

1 reference

PubMed ID

9539466